Vergados A, Mohite A A, Sung Velota C T
Birmingham and Midland Eye Centre, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Dudley Road, Birmingham, B18 7QH, UK.
Whipps Cross University Hospital, Whipps Cross Road, London, E11 1NR, UK.
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2271-2278. doi: 10.1007/s00417-019-04400-4. Epub 2019 Jul 22.
To report the 2-year outcomes of a novel surgical technique allowing reduction of the intraluminal diameter of the tube without total tube occlusion in order to allow enough increase in outflow resistance to permit resolution of hypotony whilst also achieving adequate IOP control.
This was a single-surgeon retrospective case note review of all non-valved GDD cases over an 8-year period (2008-2015) that underwent ab interno ligation of the drainage tube in order to manage post-operative hypotony (Baerveldt or Molteno). Twelve eyes of 12 patients (4.4%) developing refractory hypotony that did not respond to multiple intracameral ophthalmic viscoelastic device (OVD) injections were included in this retrospective case series and were treated with our ab interno tube ligation technique. The post-ligation management algorithm consisted of re-instating topical anti-glaucoma agents, laser suture lysis (LSL), or further ab interno ligation.
Mean IOP increased from 2.8 mmHg at baseline to 7.8 mmHg, 7.1 mmHg, 9.0 mmHg, 13.6 mmHg, 10.9 mmHg, 13.9 mmHg and 13.6 mmHg at day 1, week 1, month 1, month 3, month 6, year 1 and year 2 respectively, with or without additional topical anti-glaucoma medications. Although hypotony resolution following our technique was achieved in all eyes at 2 years, 8.3% of cases required reinstatement of topical medications to maintain IOP control within the target range.
We propose ab interno partial tube tying as an effective surgical option to achieve an immediate, predictable and sustained IOP elevation either as a primary procedure or when traditional methods have failed to resolve hypotony in eyes with non-valved GDDs.
报告一种新型手术技术的2年随访结果,该技术可在不完全闭塞引流管的情况下减小管腔内直径,从而充分增加房水流出阻力,以促进低眼压的缓解,同时实现眼压的充分控制。
这是一项由单名外科医生进行的回顾性病例记录研究,纳入了8年期间(2008 - 2015年)所有接受经内路引流管结扎术以治疗术后低眼压的无阀门青光眼引流装置(GDD)病例(Baerveldt或Molteno)。本回顾性病例系列纳入了12例患者的12只眼(4.4%),这些患者出现难治性低眼压,对多次前房内注射眼科粘弹性剂(OVD)均无反应,并接受了我们的经内路引流管结扎技术治疗。结扎术后的管理方案包括重新使用局部抗青光眼药物、激光缝线松解术(LSL)或进一步的经内路结扎术。
平均眼压从基线时的2.8 mmHg分别在术后第1天、第1周、第1个月、第3个月、第6个月、第1年和第2年升高至7.8 mmHg、7.1 mmHg、9.0 mmHg、13.6 mmHg、10.9 mmHg、13.9 mmHg和13.6 mmHg,无论是否使用额外的局部抗青光眼药物。尽管2年后所有患眼均通过我们的技术实现了低眼压缓解,但8.3%的病例需要重新使用局部药物以将眼压维持在目标范围内。
我们建议经内路部分引流管结扎术作为一种有效的手术选择,无论是作为初始手术,还是在传统方法未能解决无阀门GDD患者的低眼压问题时,都能实现眼压的即刻、可预测和持续升高。